Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Nanostart-holding MagForce AG announces company restructuring and revised corporate strategy for 2012

Abstract:
- Greater emphasis on clinical development to provide key physicians with access to NanoTherm therapy
- Start of post marketing glioblastoma study Q3 2012 to support expanded market acceptance with leading medical experts
- Enhanced activities for international partnerships and initiation of discussions with FDA
- Focus on development partnerships and strategic investors to expand patient access and further reduce development costs
- Significant decrease in operating expenses expected in 2012 through headcount reduction

Nanostart-holding MagForce AG announces company restructuring and revised corporate strategy for 2012

Berlin / Frankfurt Germany | Posted on March 26th, 2012

Nanostart (OTCQX:NASRY)-holding MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company focusing on nanomedicine in oncology announced today the company's restructuring and revised corporate strategy for 2012. The company reduced its headcount from 52 employees (year-end 2011) to 30 (April 1, 2012) and expects a significant reduction in company expenses in 2012 as compared to 2011. The implemented cost reductions will enable the company to work more effectively and concentrate on clinical development activities to support the market introduction of NanoTherm® therapy.

MagForce has revised its corporate strategy to put more emphasis on clinical development and its synergies with Marketing and Sales. The company has received EU approval for its technology, NanoTherm® therapy, for the treatment of brain tumors. Product revenues in 2011 were lower than expected due to the lack of involvement among leading medical experts in the development of the therapy. MagForce is now working closely with these key opinion leaders who have agreed to participate in a post-approval multi-center study to validate the novel technology in the medical community and gain first-hand experience.

"Our successful capital increase earlier this month along with reductions in expenditures will allow us to initiate both a glioblastoma post-market authorization study along with a study in prostate carcinoma this year. These upcoming trials, conducted in centers throughout Germany, will lay the foundation for wider acceptance of the therapy and expanded commercial use," said Dr. Andreas Jordan, Management Board and founder of MagForce. "In addition, we are in discussion with international companies and investors for strategic partnerships to share in the development costs and support international market approvals, including for the US market."

"I am delighted to be working closely with leading European key opinion leaders who are pleased to support us in the further development of NanoTherm® therapy and participate in Magforce clinical studies," said Prof. Dr. Hoda Tawfik, VP Clinical Development and Medical Affairs. "Within the multi-center studies, we expect to place two to three new NanoActivator therapy systems in strategic centers before the end of this year."

In 2012, MagForce is pursuing international partnerships, specifically in the US, and plans to initiate discussions with the FDA (Food and Drug Administration). Furthermore, the company is in discussion with strategic investors who were not able to participate in recently announced fully-subscribed capital increase, but are interested in future investment opportunities with the company.

####

About Nanostart AG
Nanostart AG (OTCQX: NASRY) headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government.

About MagForce:
MagForce AG (XETRA: MF6) is a leading medical technology company focusing on nanomedicine in oncology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com.

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.

For more information, please click here

Contacts:
Nanostart AG
Dr. Hans Joachim Duerr
Head of Corporate Communications
Goethestrasse 26-28
D-60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150

Copyright © Nanostart AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Possible Futures

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Alliances/Trade associations/Partnerships/Distributorships

Manchester graphene spin-out signs $1billion game-changing deal to help tackle global sustainability challenges: Landmark deal for the commercialisation of graphene April 14th, 2023

Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022

CEA & Partners Present ‘Powerful Step Towards Industrialization’ Of Linear Si Quantum Dot Arrays Using FDSOI Material at VLSI Symposium: Invited paper reports 3-step characterization chain and resulting methodologies and metrics that accelerate learning, provide data on device pe June 17th, 2022

University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project